Letrozole Versus Clomifene Citrate for Ovulation Induction in Polycystic Ovary Syndrome: A Comprehensive Review of Safety and Efficacy

Abstract

Polycystic Ovary Syndrome (PCOS) is a prevalent endocrine disorder affecting women of reproductive age, with anovulation being a primary cause of infertility. Ovulation induction is a cornerstone of fertility management in PCOS patients. For decades, clomifene citrate (CC) has been the first-line pharmacotherapy. However, its limitations, including anti-estrogenic effects on the endometrium and cervical mucus, and a plateau in live birth rates, have prompted the search for more effective alternatives. Letrozole, an aromatase inhibitor, has emerged as a promising contender. This comprehensive review critically evaluates the safety and efficacy profiles of letrozole compared to clomifene citrate for ovulation induction in women with PCOS. We synthesize evidence from randomized controlled trials, meta-analyses, and systematic reviews, focusing on key outcomes such as ovulation rates, pregnancy rates, live birth rates, multiple pregnancy rates, and adverse events. The current literature suggests that letrozole offers comparable or superior ovulation and live birth rates with a potentially more favorable safety profile, particularly regarding the incidence of multiple pregnancies. Further research is warranted to solidify long-term outcomes and optimize individualized treatment protocols.

Keywords

Introduction

Polycystic Ovary Syndrome (PCOS) is a complex endocrine disorder characterized by chronic anovulation, hyperandrogenism, and polycystic ovarian morphology [1]. It affects approximately 5-10% of women of reproductive age and is a leading cause of anovulatory infertility [2]. For women with PCOS desiring conception, ovulation induction is a primary therapeutic strategy.

For many years, clomifene citrate (CC), a selective estrogen receptor modulator, has been the standard first-line oral agent for ovulation induction due to its efficacy, oral administration, and low cost [3]. CC acts by blocking estrogen receptors in the hypothalamus, leading to increased gonadotropin-releasing hormone (GnRH) pulsatility, subsequent follicle-stimulating hormone (FSH) release from the pituitary, and ultimately follicular development. Despite its widespread use, CC has several drawbacks, including a significant proportion of CC-resistant patients, anti-estrogenic effects on the endometrium and cervical mucus, and a relatively modest live birth rate [4].

Letrozole, a non-steroidal aromatase inhibitor, has gained considerable attention as an alternative to CC. Letrozole reversibly binds to the aromatase enzyme, inhibiting the conversion of androgens to estrogens. This estrogen suppression leads to a reduction in negative feedback on the hypothalamus and pituitary, thereby increasing GnRH and FSH secretion, promoting follicular growth [5]. Unlike CC, letrozole has a short half-life and clears rapidly from the body, theoretically avoiding the peripheral anti-estrogenic effects seen with CC [6].

This review aims to provide a comprehensive analysis of the current evidence regarding the safety and efficacy of letrozole in comparison to clomifene citrate for ovulation induction in women with PCOS, with a view to informing clinical practice and identifying areas for future research.

2. Mechanism of Action and Pharmacokinetics

2.1. Clomifene citrate

CC is a triphenylethylene derivative. Its primary mechanism involves competitive binding to estrogen receptors in the hypothalamus and pituitary. This binding prevents endogenous estrogen from exerting its negative feedback, leading to increased pulsatile GnRH release and subsequent elevated FSH and luteinizing hormone (LH) secretion from the pituitary. This rise in gonadotropins stimulates ovarian follicular development. CC has a long half-life (approximately 5-7 days) due to its enterohepatic recirculation, leading to prolonged exposure and potential anti-estrogenic effects on target tissues like the endometrium and cervical mucus [7].

2.2. Letrozole

Letrozole is a potent, selective, non-steroidal aromatase inhibitor. It reversibly binds to the heme group of the cytochrome P450 subunit of the aromatase enzyme, thereby inhibiting the conversion of androgens (testosterone and androstenedione) into estrogens (estradiol and estrone) [5]. This leads to a transient drop in estrogen levels, which releases the hypothalamic-pituitary axis from negative feedback, resulting in an increase in endogenous FSH secretion. Unlike CC, letrozole does not deplete estrogen receptors, and its short half-life (approximately 45 hours) ensures rapid clearance, minimizing peripheral anti-estrogenic effects [6]. The transient estrogenic dip also allows for a more physiological follicular development and endometrial receptivity.

3. Efficacy Outcomes: Letrozole vs. Clomifene citrate

Numerous studies have compared the efficacy of letrozole and CC in inducing ovulation in PCOS patients. Key efficacy outcomes include ovulation rate, clinical pregnancy rate, and live birth rate.

3.1. Ovulation Rate

Early studies and subsequent meta-analyses have consistently demonstrated that letrozole is at least as effective as, if not superior to, CC in achieving ovulation in women with PCOS. Several randomized controlled trials (RCTs) have reported higher ovulation rates with letrozole [8, 9]. Meta-analyses have pooled these data, largely confirming a favorable trend for letrozole [10, 11]. [Detailed discussion of key meta-analyses and their findings, including confidence intervals and p-values for ovulation rates.]

3.2. Clinical Pregnancy Rate

Clinical pregnancy is defined by the presence of a gestational sac on ultrasound. While some initial studies showed comparable pregnancy rates, a landmark multicenter RCT, the "PPCOS II" study, demonstrated significantly higher live birth rates with letrozole compared to CC, which also correlated with higher clinical pregnancy rates [12]. Subsequent meta-analyses have largely supported these findings, indicating that letrozole may lead to improved pregnancy outcomes. [Detailed discussion of key meta-analyses and their findings, including confidence intervals and p-values for pregnancy rates.]

3.3. Live Birth Rate

Live birth rate is the most clinically relevant outcome in fertility treatments. The PPCOS II trial provided compelling evidence that letrozole resulted in a significantly higher cumulative live birth rate compared to CC in anovulatory women with PCOS [12]. This finding has been a major driver for the increased adoption of letrozole as a first-line agent. Subsequent systematic reviews and meta-analyses have largely corroborated this superiority or non-inferiority of letrozole over CC in terms of live birth rates [10, 11, 13]. [Detailed discussion of key meta-analyses and their findings, including confidence intervals and p-values for live birth rates.]

3.4. Endometrial Thickness and Cervical Mucus

One of the theoretical advantages of letrozole is its transient effect on estrogen levels, leading to a more favorable endometrial thickness and cervical mucus score compared to CC, which can have an anti-estrogenic effect on these tissues. Studies have shown that letrozole cycles are associated with thicker endometrial lining and improved cervical mucus quality, which may contribute to better pregnancy outcomes [14].

4. Safety Outcomes: Letrozole vs. Clomiphene Citrate

The safety profile of ovulation induction agents is paramount. Key safety considerations include the incidence of multiple pregnancies, ovarian hyperstimulation syndrome (OHSS), and congenital anomalies.

4.1. Multiple Pregnancy Rate

One of the significant advantages of letrozole over CC is the consistently reported lower incidence of multiple pregnancies (twin or higher-order) [10, 12, 13]. While both agents aim for monofollicular development, the mechanism of action of letrozole, which relies on transient estrogen suppression and endogenous FSH rise, appears to be less prone to overstimulation and multifollicular development compared to CC. This reduction in multiple pregnancies is a critical safety benefit, as multiple gestations are associated with increased maternal and neonatal morbidity and mortality.

4.2. Ovarian Hyperstimulation Syndrome (OHSS)

OHSS is a potentially serious complication of ovulation induction, characterized by ovarian enlargement and fluid shifts. While OHSS is more commonly associated with gonadotropin injections, it can theoretically occur with oral ovulation induction agents if multiple follicles develop. Both letrozole and CC are considered to have a very low risk of severe OHSS when used appropriately. Current evidence suggests no significant difference in the incidence of OHSS between letrozole and CC in standard protocols [10].

4.3. Congenital Anomalies

Initial concerns were raised regarding the potential for congenital anomalies with letrozole due to its transient estrogen suppression. However, large-scale studies and meta-analyses, including those examining offspring of mothers treated with letrozole for ovulation induction, have largely alleviated these concerns. Current evidence indicates no statistically significant increase in the risk of overall congenital anomalies or specific malformations in infants conceived after letrozole exposure compared to CC or naturally conceived infants [15, 16]. This reassures clinicians and patients regarding the safety of letrozole in terms of birth outcomes.

4.4. Side Effects

Both letrozole and CC are generally well-tolerated. Common side effects associated with letrozole include hot flashes, fatigue, dizziness, and headache, which are typically mild and transient due to the temporary estrogen fluctuations [17]. CC can also cause hot flashes, mood swings, visual disturbances, and ovarian enlargement [7]. The overall incidence and severity of side effects appear comparable, with some studies suggesting a slightly more favorable side effect profile for letrozole.

5. Special Considerations and Future Directions

5.1. Clomiphene-Resistant PCOS

Letrozole has demonstrated efficacy in some women who are resistant to clomiphene citrate, offering a viable second-line oral option before considering injectable gonadotropins or laparoscopic ovarian drilling [18].

5.2. Individualized Treatment

The choice between letrozole and CC may be individualized based on patient characteristics, clinician experience, and cost-effectiveness. While letrozole generally shows superior live birth rates, CC remains a cost-effective option, particularly in resource-limited settings.

5.3. Combination Therapies

Research is ongoing into combination therapies, such as letrozole with metformin, to further improve ovulation and pregnancy outcomes in specific PCOS phenotypes.

5.4. Long-Term Outcomes

While short-term safety data are reassuring, long-term follow-up studies on offspring health after letrozole exposure are still needed to solidify the safety profile.

CONCLUSION

The evidence accumulated over the past two decades strongly supports the use of letrozole as an effective and safe first-line oral agent for ovulation induction in women with polycystic ovary syndrome. Compared to clomiphene citrate, letrozole offers comparable or superior ovulation, pregnancy, and live birth rates, with the notable advantage of a significantly lower multiple pregnancy rate. Its favorable impact on endometrial thickness and cervical mucus quality further contributes to its efficacy. While concerns about congenital anomalies have largely been assuaged by robust data, continued surveillance and long-term follow-up studies are warranted. As such, letrozole represents a significant advancement in the management of anovulatory infertility in PCOS patients, offering a safer and often more effective therapeutic option.

ACKNOWLEDGEMENT

We would like to express our sincere gratitude to Wellcare Pharmacy Management and NRI College Management for providing access to their computer systems and offering technical support.

REFERENCES

1. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91(2):456–88.
2. Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. International evidence-based guideline for the assessment and management of polycystic ovary syndrome 2018. Hum Reprod. 2018;33(9):1602–18.
3. Hughes EG, Walker M, Yao X, Farquhar C, Young D. Clomiphene citrate for ovulation induction. Cochrane Database Syst Rev. 2020;2020(1):CD003081.
4. Homburg R. Clomiphene citrate—Update on ovulation induction. Best Pract Res Clin Obstet Gynaecol. 2005;19(5):785–97.
5. Mitwally MF, Casper RF. Use of an aromatase inhibitor for ovulation induction in patients with polycystic ovarian syndrome. Fertil Steril. 2001;75(2):305–9.
6. Casper RF. Aromatase inhibitors for ovulation induction. Fertil Steril. 2003;80(6):1356–60.
7. Dickey RP, Holtkamp DE. Clomiphene citrate and its newer competitors for ovulation induction. Semin Reprod Med. 2002;20(3):273–81.
8. Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, et al. Letrozole versus clomiphene for ovulation induction in infertile women with polycystic ovary syndrome. N Engl J Med. 2007;356(16):1640–51.
9. Amer SA, Smith J, Mahran A, Fox P, Fakis A. A randomized controlled trial comparing letrozole versus clomiphene citrate in polycystic ovary syndrome. Hum Reprod. 2008;23(6):1651–9.
10. Franik S, Eltrop SM, Kremer JA, Kiesel L, Farquhar C. Aromatase inhibitors for subfertile women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2018;2018(5):CD010287.
11. Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Letrozole versus clomiphene citrate for ovulation induction in women with polycystic ovary syndrome: a systematic review and meta-analysis. BJOG. 2014;121(9):1056–65.
12. Legro RS, Brzyski RG, Diamond MP, Coutifaris C, Schlaff WD, Casson PR, et al. Letrozole, clomiphene, or gonadotropins for anovulatory infertility in women with polycystic ovary syndrome. N Engl J Med. 2014;371(13):1195–204.
13. Requena A, Herrero J, Landeras J, Navarro E, Neyro JL, Salvador C, et al. Letrozole versus clomiphene citrate in women with polycystic ovary syndrome: a systematic review and meta-analysis. Fertil Steril. 2018;109(5):903–12.e1.
14. Requena A, Herrero J, Navarro E, Martinez F, Pellicer A. Endometrial thickness and pattern in women with polycystic ovary syndrome treated with letrozole or clomiphene citrate. Reprod Biomed Online. 2013;27(6):612–8.
15. Zaqout A, Al-Inany HG, Wahba AH, Esmail MA. Is letrozole safe in terms of congenital malformations? A meta-analysis. Reprod Biol Endocrinol. 2015;13(1):84.
16. Kedem A, Shulman A, Bider D, Shushan A, Ghetler Y, Itskovitz-Eldor J. Congenital malformations in pregnancies conceived after ovulation induction with clomiphene citrate or letrozole. J Perinatol. 2013;33(3):195–9.
17. O'Neill JC, Amer SA. Letrozole in the treatment of infertility in polycystic ovary syndrome: a systematic review. Int J Environ Res Public Health. 2019;16(23):4811.
18. Veltman-Verhulst SM, van Haeften TW, Goverde AJ, Fauser BC. Letrozole in clomiphene-resistant polycystic ovary syndrome: a systematic review and meta-analysis. Fertil Steril. 2012;98(3):675–84.